Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer

Clinical Lung Cancer

Volumn 10, Issue SUPPL.1, 2009, Pages

  Horn, Leora ^a   Sandler, Alan B ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Axitinib; Bevacizumab; BIBF 1120; Cediranib; Motesanib; Multikinase inhibitors; Pazopanib; Sorafenib; Sunitinib; Thalidomide; Vandetanib; Vascular endothelial growth factor; XL647

Indexed keywords

ANGIOGENESIS INHIBITOR; BENZENESULFONIC ACID DERIVATIVE; BEVACIZUMAB; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 ((1 METHYLPIPERIDIN 4 YL)METHOXY)QUINAZOLIN 4 AMINE; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE; SORAFENIB; SUNITINIB; THALIDOMIDE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

CLINICAL TRIAL; DRUG ANTAGONISM; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; REVIEW; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BENZENESULFONATES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; INDOLES; LUNG NEOPLASMS; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; QUINAZOLINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; THALIDOMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67449107060     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.3816/CLC.2009.s.002     Document Type: Review

References (96)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96. (Pubitemid 351521864)
2. Lung Cancer Principles and Practice. Pass HI, Johnson DH, Carbon DP, et al, eds. Philadelphia, PA: Lippincott Williams & Wilkins, 2005.
3. Pignon J-P, Tribodet H, Scagliotti GV, et al. Lung Adjuvant Cisplatin Evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol 2008; 26:3552-9.
4. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-8. (Pubitemid 34438899)
5. Yano S, Shinohara H, Herbst RS, et al. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res 2000; 60:4959-67.
6. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-6.
7. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-64. (Pubitemid 26272076)
8. Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006; 312:1171-5. (Pubitemid 43801134)
9. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005; 15:102-11. (Pubitemid 40127638)
10. Macchiarini P, Fontanini G, Dulmet E, et al. Angiogenesis: an indicator of metastasis in non-small cell lung cancer invading the thoracic inlet. Ann Thorac Surg 1994; 57:1534-9. (Pubitemid 24216322)
11. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1:149-53.
12. Fontanini G, Bigini D, Vignati S, et al. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol 1995; 177:57-63.
13. Fontanini G, Lucchi M, Vignati S, et al. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst 1997; 89:881-6. (Pubitemid 27268454)
14. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22:2184-91. (Pubitemid 41095154)
15. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50. (Pubitemid 44917502)
16. Manegold C, von Pawel J, Zatloukal P, et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous nonsmall cell lung cancer (NSCLC): BO17704. J Clin Oncol 2007; 25(18 suppl):388s (Abstract LBA7514).
17. Davila E, Lilenbaum R, Raez L, et al. Phase II trial of oxaliplatin and gemcitabine with bevacizumab in first-line advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006; 24(18 suppl):667s (Abstract 17009).
18. Waples JM, Auerbach M, Steis R, et al. A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer (An International Oncology Network study, #I-04-015). J Clin Oncol 2008; 26(15 suppl):707s (Abstract 19018).
19. Adjei AA, Mandrekar SJ, Dy GK, et al. A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced nonsmall cell lung cancer (NSCLC): an NCCTG and SWOG study. J Clin Oncol 2008; 26(15 suppl)443s (Abstract 8080).
20. Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007; 25:4743-50. (Pubitemid 350086476)
21. Gutierrez M, Kummar S, Allen D, et al. A phase II study of multikinase inhibitor sorafenib in patients with relapse non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26(15 suppl)712s (Abstract 19084).
22. Gatzemeier U, Blumenschein G, Fosella F, et al. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 2006; 24(18 suppl):364s (Abstract 7002).
23. Adjei AA, Molina JR, Hillman SL, et al. A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol 2007; 25(18 suppl):396s (Abstract 7547).
24. Adjei AA, Molina JR, Mandrekar SJ, et al. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res 2007; 13:2684-91. (Pubitemid 46788036)
25. Schiller JH, Flaherty KT, Redlinger M, et al. Sorafenib combined with carboplatin/ paclitaxel for advanced non-small cell lung cancer: a phase I subset analysis. J Clin Oncol 2006; 24(18 suppl):412s (Abstract 7194).
26. Scagliotti G, Von Pawel J, Reck M, et al. Phase III Trial comparing carboplatin and paclitaxel with or without sorafenib in chemonaive patients with stage IIIB (with effusion) or IV non-small cell lung cancer. Paper presented at: The 1st IASLC-ESMO European Lung Cancer Conference 2008; Geneva, Switzerland; April 23-26, 2008.
27. Kiura K, Nakagawa K, Shinkai T, et al. A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol 2008; 3:386-93. (Pubitemid 351489479)
28. Natale RB, Bodkin D, Govindan R, et al. ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, double-blind, randomized phase II trial. J Clin Oncol 2006; 24(18 suppl):364s (Abstract 7000).
29. Heymach JV, Johnson BE, Prager D, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007; 25:4270-7. (Pubitemid 47548567)
30. Heymach J, Paz-Ares L, De Braud F, et al. Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(18 suppl):395s (Abstract 7544).
31. Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008; 26:650-6. (Pubitemid 351264362)
32. Brahmer JR, Govindan R, Novello S, et al. Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): results from a phase II study. J Clin Oncol 2007; 25(18 suppl):395s (Abstract 7542).
33. Reck M, Frickhofen N, Gatzemeier U, et al. A phase I dose escalation study of sunitinib in combination with gemcitabine + cisplatin for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(18 suppl):688s (Abstract 18057).
34. Miller AA, Case D, Atkins J, et al. Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004; 22:646 (Abstract 7132).
35. Lee S, Rudd RM, Woll PJ, et al. Two randomised phase III, double-blind, placebo controlled trials of thalidomide in patients with advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). J Clin Oncol 2008; 26(15 suppl):435s (Abstract 8045).
36. Flora DB, Kleykamp B, Knapp M, et al. A phase II trial of thalidomide (T), irinotecan (I) and gemcitabine (G) in chemonaive patients (pts) with advanced nonsmall cell lung cancer (NSCLC). J Clin Oncol 2004; 22:670 (Abstract 7258).
37. Seidler CW, Scepansky E, Khanani S, et al. Phase I-II trial of daily thalidomide in combination with docetaxel in patients with relapsed non-small cell lung cancer: A final analysis. J Clin Oncol 2006; 24(18 suppl):671s (Abstract 17060).
38. Laurie SA, Gauthier I, Arnold A, et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2008; 26:1871-8.
39. Schiller JH, Larson T, Ou SI, et al. Efficacy and safety of axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial. J Clin Oncol 2007; 25(18 suppl):386s (Abstract 7507).
40. Miller VA, Wakelee HA, Lara PN, et al. Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: preliminary results of a phase II trial. J Clin Oncol 2008; 26(15 suppl):430s (Abstract 8028).
41. Rizvi NA, Kris MG, Miller VA, et al. Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations. Result from phase 2. J Clin Oncol 2008; 26 (Abstract 8053).
42. Imoto H, Osaki T, Taga S, et al. Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 1998; 115:1007-14. (Pubitemid 28224393)
43. Volm M, Koomagi R, Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 1997; 74:64-8. (Pubitemid 27157857)
44. Fontanini G, Faviana P, Lucchi M, et al. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 2002; 86:558-63. (Pubitemid 34185092)
45. Fontanini G, Vignati S, Boldrini L, et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997; 3:861-5. (Pubitemid 27252933)
46. Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3:391-400. (Pubitemid 38618122)
47. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57:4593-9. (Pubitemid 27441066)
48. Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, advancedstage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008; 26:60-5.
49. National Cancer Institute [Web site] Available at: www.cancer.gov. Accessed: February 25, 2009.
50. Reynolds C, Barrera D, Vu DQ, et al. An open-label, phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab in firstline patients with advanced non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(18 suppl):411s (Abstract 7610).
51. William WN Jr, Kies MS, Fossella FV, et al. Phase II study of bevacizumab in combination with docetaxel and carboplatin in patients with metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(18 suppl):691s (Abstract 18098).
52. Dalsania CJ, Hageboutros A, Harris E, et al. Phase II trial of bevacizumab plus pemetrexed and carboplatin in previously untreated advanced nonsquamous nonsmall cell lung cancer. J Clin Oncol 2007; 25(18 suppl):691s (Abstract 18163).
53. Patel JD, Hensing TA, Villafor V, et al. Pemetrexed and carboplatin plus bevacizumab for advanced non-squamous non-small cell lung cancer (NSCLC): preliminary results. J Clin Oncol 2007; 25(18 suppl):409s (Abstract 7601).
54. Rizvi NA, Rusch V, Zhao B, et al. Single agent bevacizumab and bevacizumab in combination with docetaxel and cisplatin as induction therapy for resectable IB-IIIA non-small cell lung cancer. J Clin Oncol 2007; 25(18 suppl):687s (Abstract 18045).
55. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589-97. (Pubitemid 41079796)
56. Akerley WL, Langer CJ, Oh Y, et al. Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer. J Clin Oncol 2008; 26(15 suppl):434s (Abstract 8043).
57. Dansin E, Mezger J, Isla D, et al. Safety of bevacizumab-based therapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): MO19390 (SAiL). J Clin Oncol 2008; 26(15 suppl):445s (Abstract 8085).
58. Griesinger F, Laskin JJ, Pavlakis N, et al. Safety of first-line bevacizumab-based therapy with concomitant cardiovascular or anticoagulation medication in advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in MO19390 (SAiL). J Clin Oncol 2008; 26(15 suppl):436s (Abstract 8049).
59. Lynch TJ, Brahmer J, Fischbach N, et al. Preliminary treatment patterns and safety outcomes for non-small cell lung cancer (NSCLC) from ARIES, a bevacizumab treatment observational cohort study (OCS). J Clin Oncol 2008; 26(15 suppl):443s (Abstract 8077).
60. Carter C, Chen C, Brink C, et al. Sorafenib is efficacious and tolerated in combination with cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother Pharmacol 2006; 59:183-95. (Pubitemid 44885148)
61. Wilhelm S, Chien DS. BAY 43-9006: preclinical data. Curr Pharm Des 2002; 8:2255-7. (Pubitemid 35189898)
62. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004; 10:6388S-92S. (Pubitemid 39302607)
63. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-109. (Pubitemid 39331023)
64. Murphy DA, Makonnen S, Lassoued W, et al. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am J Pathol 2006; 169:1875-85.
65. Liu B, Barrett T, Choyke P, et al. A phase II study of BAY 43-9006 (Sorafenib) in patients with relapsed non-small cell lung cancer (NSCLC). J Clin Oncol 2006; 24(18 suppl)676s (Abstract 17119).
66. Schiller JH, Lee JW, Hanna NH, et al. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. J Clin Oncol 2008; 26(15 suppl):427s (Abstract 8014).
67. Bukowski R, Cella D, Gondek K, et al. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 2007; 30:220-7. (Pubitemid 46884139)
68. Johnson BE, Ma P, West H, et al. Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC. J Clin Oncol 2005; 23(16 suppl):645s (Abstract 7102).
69. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-32. (Pubitemid 41058344)
70. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22:3238-47. (Pubitemid 41103678)
71. Ellis LM. Epidermal growth factor receptor in tumor angiogenesis. Hematol Oncol Clin North Am 2004; 18:1007-21 viii. (Pubitemid 39335756)
72. Vallbohmer D, Zhang W, Gordon M, et al. Molecular determinants of cetuximab efficacy. J Clin Oncol 2005; 23:3536-44.
73. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 2007; 5:203-20. (Pubitemid 46569773)
74. Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2:471-8.
75. Robert F, Sandler A, Schiller JH, et al. A phase I dose-escalation and pharmacokinetic (PK) study of sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors (STs). J Clin Oncol 2007; 25(18 suppl):148s (Abstract 3543).
76. Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004; 363:1802-11. (Pubitemid 38698386)
77. Lorusso PM, Heath E, Valdivieso M, et al. Phase I evaluation of AZD2171, a highly potent and selective inhibitor of VEGFR signaling, in combination with selected chemotherapy regimens in patients with advanced solid tumors. J Clin Oncol 2006; 24(18 suppl):129s (Abstract 3034).
78. van Cruijsen H, Voest EE, van Herpen CML, et al. Phase I clinical evaluation of AZD2171 in combination with gefitinib, in patients with advanced tumors. J Clin Oncol 2005; 23(16 suppl):199s (Abstract 3030).
79. Goss GD, Laurie S, Shepherd F, et al. IND.175: Phase I study of daily oral AZD2171, a vascular endothelial growth factor receptor inhibitor (VEGFRI), in combination with gemcitabine and cisplatin (G/C) in patients with advanced nonsmall cell lung cancer (ANSCLC): A study of the NCIC Clinical Trials Group. J Clin Oncol 2007; 25(18 suppl):421s (Abstract 7649).
80. Rosen L, Kurzrock R, Jackson E, et al. Safety and pharmacokinetics of AMG 706 in patients with advanced solid tumors. J Clin Oncol 2005; 23(16 suppl):195s (Abstract 3013).
81. Price TJ, Lipton L, Williams J, et al. Safety and pharmacokinetics (PK) of AMG 706 in combination with gemcitabine for the treatment of patients (pts) with solid tumors. J Clin Oncol 2007; 25(18 suppl):612s (Abstract 14005).
82. Blumenschein G, Jr, Sandler A, O'Rourke T, et al. Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006; 24(18 suppl):393s (Abstract 7119).
83. Crawford J, Burris H, Stephenson J, Jr, et al. Safety and pharmacokinetics (PK) of AMG 706 in combination with panitumumab and gemcitabine-cisplatin in patients (pts) with advanced cancer. J Clin Oncol 2007; 25(18 suppl):616s (Abstract 14057).
84. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005; 23:5474-83.
85. Hurwitz H, Dowlati A, Savage S, et al. Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. J Clin Oncol 2005; 23(16 suppl):195s (Abstract 3012).
86. Nikolinakos P, Altorki N, Guarino M, et al. Analyses of plasma cytokine/angiogenic factors (C/AFs) profile during preoperative treatment with pazopanib (GW786034) in early-stage non-small cell lung cancer. J Clin Oncol 2008; 26(15 suppl):414s (Abstract 7568).
87. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008; 68:4774-82.
88. Mross KB, Gmehling D, Frost A, et al. A clinical phase I, pharmacokinetic (PK), and pharmacodynamic study of twice daily BIBF 1120 in advanced cancer patients. J Clin Oncol 2005; 23(16 suppl):199s (Abstract 3031).
89. Von Pawel J, Kaiser R, Eschbach C, et al. A double-blind phase II study of BIBF 1,120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(18 suppl):418s (Abstract 7635).
90. Hanna N, Ellis P, Stopfer P, et al. A phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 together with pemetrexed in previously treated patients with non-small cell lung cancer: P3-091. J Thorac Oncol 2007; 2:S717-8.
91. Wakelee HA, Adjei AA, Halsey J, et al. A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM). J Clin Oncol 2006; 24(18 suppl):131s (Abstract 3044).
92. Wakelee H, Adjei AA, Keer H, et al. A phase I dose-escalation and pharmacokinetic (PK) study of a novel multiple-targeted receptor tyrosine kinase (RTK) inhibitor, XL647, in patients with advanced solid malignancies. J Clin Oncol 2005; 23(16 suppl):227s (Abstract 3142).
93. Wakelee HA, Fehling JM, Molina JR, et al. A phase I study of XL647, an EGFR, HER2, VEGFR2 inhibitor, administered orally daily to patients (pts) with advanced solid malignancies (ASM). J Clin Oncol 2008; 26(15 suppl):160s (Abstract 3528).
94. Beliveau R, Gingras D, Kruger EA, et al. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. Clin Cancer Res 2002; 8:1242-50. (Pubitemid 35177381)
95. Boivin D, Gendron S, Beaulieu E, et al. The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis. Mol Cancer Ther 2002; 1:795-802.
96. Latreille J, Batist G, Laberge F, et al. Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. Clin Lung Cancer 2003; 4:231-6. (Pubitemid 36758172)